Skip to content

Real-time Intervention for Suicide Risk Reduction: Primary Open Pilot

Real-time Intervention for Suicide Risk Reduction

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03950765
Enrollment
25
Registered
2019-05-15
Start date
2019-07-29
Completion date
2020-04-15
Last updated
2026-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Suicide, Attempted, Suicide and Self-harm

Keywords

ecological momentary assessment, ecological momentary intervention, distress

Brief summary

The goal of this study is to provide an initial pilot test of an Ecological Momentary Intervention (EMI) designed the reduce the distress associated with negative emotion among individuals at risk for suicide that pairs content from a smartphone with a wearable physiological monitor. Participants will be 25 suicidal adult inpatients who will complete three brief therapy sessions with a study therapist and then complete exercises associated with the study for the duration of the inpatient period and for 28 days after they leave the hospital.

Detailed description

The goal of this study is to provide an initial pilot test of an Ecological Momentary Intervention (EMI) designed the reduce the distress associated with negative emotion among individuals at risk for suicide that pairs content from a smartphone with a wearable physiological monitor. Participants will be 25 suicidal adult inpatients who will complete three brief therapy sessions with a study therapist and then complete exercises associated with the study for the duration of the inpatient period and for 28 days after they leave the hospital. During the time they are in the study, participants will be asked to install on their smartphone a mobile application to deliver the therapeutic content and will wear a physiological monitoring device on their wrist (Empatica Embrace) which will monitor objective signals of physiological distress (e.g., skin conductance).

Interventions

Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.

Sponsors

Rutgers, The State University of New Jersey
Lead SponsorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH
Massachusetts General Hospital
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* A recent suicide attempt or serious suicidal ideation (i.e., ideation with at least 70% intent or a suicide plan with access to lethal means), * The ability to speak and write English fluently, access to an internet-capable smartphone (e.g., an iPhone or Android phone) * Providing at least one collateral contact in cases where the investigators cannot reach the participant.

Exclusion criteria

* The presence of any factor that impairs an individual's ability to comprehend and effectively participate in the study including: * An inability to speak or write English fluently * The presence of gross cognitive impairment due to florid psychosis, intellectual disability, dementia, or acute intoxication. * The presence of extremely agitated or violent behavior.

Design outcomes

Primary

MeasureTime frameDescription
Self Reported DistressImmediately before and immediately after each in-app skills-practice exercise, over days 1-28 post-discharge. Each participant's pre-practice and post-practice ratings were averaged across all exercises completed during this period.Self-reported momentary distress, computed as the sum of four items (hopelessness, anger, burdensomeness, agitation), each rated 0-10. Composite range 0-40. Higher scores indicate greater (worse) distress.
Skin Conductance ResponseUp to 42 days (from enrollment during the inpatient psychiatric stay, up to 14 days, through 28 days after hospital discharge)Total number of skin conductance responses, assessed via electrodermal activity recorded with a wrist-worn wearable device.
Momentary Suicidal ThinkingUp to 42 days (from enrollment during the inpatient psychiatric stay, up to 14 days, through 28 days after hospital discharge)This is an 11-point scale. A score of 0 is equivalent to no suicidal thinking at all ("not at all"), a score of 10 is a score of very extreme suicidal thinking ("Extremely"). Lower scores equal less severe suicidal thinking (i.e., a better outcome). Ratings were collected immediately before and immediately after each in-app skills-practice exercise. Each participant's pre-practice and post-practice ratings were averaged across all exercises completed during the study period; values are the mean (SD) across participants of these per-participant averages.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATOREvan Kleiman

Harvard University

Participant flow

Recruitment details

Participants (n = 25) were recruited as part of a registered clinical trial (NCT03950765) from the Massachusetts General Hospital inpatient psychiatry service between July 2019 and March 2020.

Baseline characteristics

Characteristic—
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
25 Participants
Age, Continuous33.48 years
STANDARD_DEVIATION 13.84
Patient-Reported Outcomes Measurement Information System Self-efficacy for managing emotions33.53 t-score
STANDARD_DEVIATION 4.66
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
4 Participants
Race (NIH/OMB)
Black or African American
2 Participants
Race (NIH/OMB)
More than one race
1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
3 Participants
Race (NIH/OMB)
White
15 Participants
Region of Enrollment
United States
25 participants
Sex: Female, Male
Female
14 Participants
Sex: Female, Male
Male
11 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 25
other
Total, other adverse events
0 / 25
serious
Total, serious adverse events
0 / 25

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Oct 28, 2026